Genetic Technology (Precision Breeding) Bill (First sitting)

Debate between Ruth Jones and John Howell

Committee stage
Tuesday 28th June 2022 Public Bill Committees

[John Howell (Henley) (Con)]

Q Earlier, you were asked about our relationship with the EU on this matter, and you mentioned progress in precision breeding across the world. How does that fit together, where is most of the research taking place, and which countries should we look at to make comparisons with the UK?

Dr Ferrier: Certainly, the most recent development in countries reviewing their legislation, and one that I think would be really useful for you to look at, is what Health Canada, the Canadian authority, has done. It has recently reviewed its legislation and put out some technical guidance. The key thing is that it confirms that precision bred organisms do not pose any additional safety risks compared with conventionally bred plant varieties. That is driving Canada’s regulatory process. It is not proposing different authorisation and risk-assessment processes. It does not believe that that would add any significant benefit for consumers or the environment, because the science does not show any additional risks—that is very similar to the European Food Safety Authority opinion from the end of November 2020.

Argentina is certainly a very interesting case. Since it has put in place proportionate and enabling regulations—such as those that the Government propose in this Bill—it has seen a real increase in the number of small and medium-sized enterprises and public-good breeding R&D activities taking products through that regulatory process, so that it is not just the preserve of the largest companies that are able to pay for and absorb any uncertainty in a less ideal or dysfunctional regulatory process.

Japan is another example of where a product—a tomato—has been through that process. In countries that put in place proper regulation, the actual process is functional and works well for the companies. Those countries then see investment in R&D and into commercial companies. That is bringing through the products. South America, North America and Japan are investing in this. It is interesting to see how quickly the science develops into commercial opportunities once the regulations are right.

David Exwood: The challenges that we face as farmers in the UK—sustainability, climate change and so on—are the challenges faced by farmers across the world, and we are all looking for solutions to those problems. It is interesting that across the world, there is a move on this technology, which we are seeing quite widely. That is because everybody is looking for answers and solutions to the challenges that we all face.

[Ruth Jones (Newport West) (Lab)]

Q I thank the witnesses for their time. I want to turn to animals specifically, which some people are surprised to see included in the Bill so early on. Animal welfare charities are anxious that using gene editing to improve productivity and disease resistance could lead to more intensive farming. What would you say to that?

Dr Ferrier: There is no evidence that that would be the case, but we understand that people have concerns about existing farming systems. We see that expressed, and we work hard to address it. To me, that is a separate issue from the Bill. We can have discussions about how to improve animal welfare, but I really do not think that it would be sensible, I guess, to design special elements of this particular Bill to address general concerns about farming systems.

The other important thing to be aware of is all the existing animal welfare rules and activities within Government and industry. Obviously the Animal Welfare Act 2006 applies, so we need not duplicate elements of that in the Bill, and there are codes of practice for each sector that are being reviewed all the time. Also, the action plan for animal welfare is in place, and the animal welfare pathway is being developed. We therefore think that concerns in the area, which are freely expressed, are being, and can be, dealt with through appropriate parts of legislation and industry action.

The Bill, which relates to just one particular technology, is not the place to address those areas. We have talked about the challenges. It is not just a challenge for growers of crops; there are a lot of difficulties that are climate change-related, and disease, health and welfare-related production challenges for farmers. There are genetic solutions to some of those challenges that we would like to see explored. We would like farmers to have the benefit of them, but we will only be able to explore them if the legislation enables companies to invest in the technologies to work out whether some of them could help. We can only see benefit from using this technology to address some of those problems.